ALK is altered in 1.96% of pancreatic adenocarcinoma patients [2].

ALK is an inclusion eligibility criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ALK status and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

ARID1A is altered in 8.97% of pancreatic adenocarcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is altered in 4.2% of pancreatic adenocarcinoma patients [2].

ATM is an inclusion eligibility criterion in 7 clinical trials for pancreatic adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain ATM status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [3].

ATR is altered in 1.41% of pancreatic adenocarcinoma patients [2].

ATR is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain ATR status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

ATRX is altered in 1.18% of pancreatic adenocarcinoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BAP1 is altered in 0.7% of pancreatic adenocarcinoma patients [2].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 1.19% of pancreatic adenocarcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain BARD1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

BLM is altered in 1.1% of pancreatic adenocarcinoma patients [2].

BLM is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BLM status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 2.5% of pancreatic adenocarcinoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [3].

BRCA1 is altered in 2.0% of pancreatic adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 10 clinical trials for pancreatic adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain BRCA1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].

Olaparib has evidence of efficacy in patients with BRCA1 mutation in pancreatic adenocarcinoma [3].

BRCA2 is altered in 5.19% of pancreatic adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 10 clinical trials for pancreatic adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain BRCA2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].

Olaparib has evidence of efficacy in patients with BRCA2 mutation in pancreatic adenocarcinoma [3].

BRIP1 is altered in 1.27% of pancreatic adenocarcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRIP1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

C11orf30 is altered in 0.21% of pancreatic adenocarcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 1.52% of pancreatic adenocarcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain CDK12 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

CHEK1 is altered in 0.52% of pancreatic adenocarcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain CHEK1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

CHEK2 is altered in 0.81% of pancreatic adenocarcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 7 clinical trials for pancreatic adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain CHEK2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 1.02% of pancreatic adenocarcinoma patients [2].

EGFR is an inclusion eligibility criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

ERBB2 is altered in 2.15% of pancreatic adenocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ERBB3 is altered in 1.77% of pancreatic adenocarcinoma patients [2].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC2 is altered in 1.49% of pancreatic adenocarcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC3 is altered in 0.38% of pancreatic adenocarcinoma patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC4 is altered in 0.67% of pancreatic adenocarcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC5 is altered in 0.97% of pancreatic adenocarcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC6 is altered in 0.51% of pancreatic adenocarcinoma patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FAM175A is altered in 0.18% of pancreatic adenocarcinoma patients [2].

FAM175A is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FAM175A status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 1.69% of pancreatic adenocarcinoma patients [2].

FANCA is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain FANCA status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

FANCB is altered in 0.29% of pancreatic adenocarcinoma patients [2].

FANCB is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCB status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCC is altered in 0.48% of pancreatic adenocarcinoma patients [2].

FANCC is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain FANCC status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

FANCD2 is altered in 11.28% of pancreatic adenocarcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCD2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCE is altered in 0.74% of pancreatic adenocarcinoma patients [2].

FANCE is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCE status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCF is altered in 0.43% of pancreatic adenocarcinoma patients [2].

FANCF is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCF status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCG is altered in 1.68% of pancreatic adenocarcinoma patients [2].

FANCG is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCG status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCI is altered in 1.71% of pancreatic adenocarcinoma patients [2].

FANCI is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCI status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCL is altered in 0.88% of pancreatic adenocarcinoma patients [2].

FANCL is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCL status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCM is altered in 2.59% of pancreatic adenocarcinoma patients [2].

FANCM is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCM status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FGFR1 is altered in 1.98% of pancreatic adenocarcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is altered in 0.9% of pancreatic adenocarcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC1 is altered in 0.69% of pancreatic adenocarcinoma patients [2].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is altered in 0.2% of pancreatic adenocarcinoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is altered in 86.35% of pancreatic adenocarcinoma patients [2].

KRAS is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS status and pancreatic adenocarcinoma as inclusion criteria, 4 are phase 1 (4 open) and 2 are phase 1/phase 2 (2 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K1 is altered in 0.22% of pancreatic adenocarcinoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K2 is altered in 0.4% of pancreatic adenocarcinoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K4 is altered in 2.34% of pancreatic adenocarcinoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K5 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K6 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K7 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K7 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK1 is altered in 0.2% of pancreatic adenocarcinoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK3 is altered in 0.18% of pancreatic adenocarcinoma patients [2].

MAPK3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain MCPH1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

MDM2 is altered in 0.99% of pancreatic adenocarcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM4 is altered in 0.33% of pancreatic adenocarcinoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is altered in 0.9% of pancreatic adenocarcinoma patients [2].

MET is an inclusion eligibility criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 is altered in 0.69% of pancreatic adenocarcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is altered in 0.88% of pancreatic adenocarcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 0.4% of pancreatic adenocarcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain MRE11A status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

MSH2 is altered in 1.21% of pancreatic adenocarcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 is altered in 0.63% of pancreatic adenocarcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 1.36% of pancreatic adenocarcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MUTYH is altered in 0.56% of pancreatic adenocarcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is altered in 1.03% of pancreatic adenocarcinoma patients [2].

NBN is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain NBN status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

NPM1 is altered in 0.32% of pancreatic adenocarcinoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is altered in 0.72% of pancreatic adenocarcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is altered in 1.29% of pancreatic adenocarcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 8 clinical trials for pancreatic adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain PALB2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (6 open) [3].

PARP1 is altered in 0.65% of pancreatic adenocarcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is altered in 0.41% of pancreatic adenocarcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 0.83% of pancreatic adenocarcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 1.51% of pancreatic adenocarcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R1A is altered in 0.51% of pancreatic adenocarcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 1.1% of pancreatic adenocarcinoma patients [2].

PTEN is an inclusion eligibility criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

RAD50 is altered in 1.01% of pancreatic adenocarcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain RAD50 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

RAD51 is altered in 0.15% of pancreatic adenocarcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain RAD51 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

RAD51B is altered in 0.13% of pancreatic adenocarcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51B status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

RAD51C is altered in 0.44% of pancreatic adenocarcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain RAD51C status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

RAD51D is altered in 0.18% of pancreatic adenocarcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51D status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

RAD54L is altered in 0.43% of pancreatic adenocarcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD54L status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

RET is altered in 1.22% of pancreatic adenocarcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RNF43 is altered in 6.13% of pancreatic adenocarcinoma patients [2].

RNF43 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ROS1 is altered in 2.03% of pancreatic adenocarcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RSPO1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RTEL1 is altered in 0.82% of pancreatic adenocarcinoma patients [2].

RTEL1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RTEL1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 1.29% of pancreatic adenocarcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain SLX4 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

SMARCB1 is altered in 0.28% of pancreatic adenocarcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is altered in 0.89% of pancreatic adenocarcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STK11 is altered in 2.07% of pancreatic adenocarcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 68.68% of pancreatic adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains UGT1A1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

XRCC1 is altered in 0.86% of pancreatic adenocarcinoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].